Developed and commercialized TYRVAYA (varenicline solution) nasal spray for dry eye disease. Focused on pharmaceutical therapies for ophthalmic diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 57% below its peak. The market has trimmed its expectations for the company.
Sales run at $24.5M a year. A small number, but proof the product has real buyers.
A loss of $104.4M against $24.5M in annual sales.
At the current pace of spending, the cash lasts about 1.9 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.